FCF Biotech Venture Capital Monitor – USA 05/2023 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 05/2023”.

The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector.

As of the end of  May 2023, we identify the following current VC trends in the US-Biotech sector:

  • In 2023, overall Biotech funding in the USA has reached USD 7,600m
  • Compared to May 2022 the financing volume decreased by more than 60% (17,091m vs. 7,600m)
  • The top 5 deals exceed USD 190m each, the largest transaction amounted to USD 401m with ElevateBio
  • ARCH Venture Partners (USA) is leading the Top 5 Investors (by deal volume), followed by New Enterprise Associates (USA) and OrbiMed (USA)
  • As an indication oncology records the highest investment activity

To access the full report, please click here.

By Mathias Klozenbücher, Johannes Link and Marcel-Louis Christou.